Evaluating the Therapeutic Efficacy of Habb-e-Ghafis in Non-alcoholic Fatty Liver Disease, a Randomised, Single-Blind, Standard-Controlled Trial

Abstract

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a prevalent metabolic disorder. Its emergence as a major health challenge has prompted a re-evaluation of therapeutic approaches, particularly considering the limitations associated with prevailing conventional treatments. It was hypothesized that Habb-e-Ghafis may exhibit therapeutic properties capable of ameliorating the pathological processes associated with NAFLD. The aim of the study was to evaluate the safety and efficacy of Habb-e-Ghafis in the treatment of non-alcoholic fatty liver disease.

Methods

This was a single-blind, randomised, standard-controlled clinical study. The study involved 44 non-alcoholic fatty liver disease patients, with 42 completing the trial. The study was approved by the Institutional Ethics Committee (IEC No.: RRIUMSGR/ MD-2019/CT/HG/NAFLD) on November 26, 2021, and registered with the Clinical Trials Registry-India (CTRI/2022/01/039497) on January 17, 2022. Patient recruitment commenced in March 2022 at RRIUM Hospital. The test group (22 patients) received Habb-e-Ghafis (3 pills, thrice daily) for 45 days, while the control group (22 patients) received Vitamin E (400 mg twice daily).

Results

Our study revealed the remarkable effectiveness of Habb-e-Ghafis in alleviating subjective symptoms. It significantly reduced liver span as quantified by Ultrasonography when compared to the standard medication. Concerning lipid profiles, the experimental drug notably reduced triglycerides and very low-density lipoprotein levels in comparison to the standard drug. Other lipid parameters showed similar effects in both treatment groups.

Conclusions

The results of this study suggest that Habb-e-Ghafis is more effective than the standard drug Vitamin E at reducing both subjective and objective parameters.